The most common adverse effects of the therapy with Rosuvastatin and other HMG-CoA reductase inhibitors are gastrointestinal disturbances. Other adverse effects reported include headache, skin rashes, dizziness, blurred vision and dysgeusia reversible increase in serum-aminotransferase concentrations may occur and liver functions should be monitored. Myopathy characterized by myalgia and muscle weakness and associated with increase creatinine phosphokinase concentrations, has been reported specially in patients taking Rosuvastatin concurrently with immunosuppressive drugs, fibric acid derivatives or nicotinic acid. Rarely rhabdomyolysis with acute renal failure may develop.